New factors controlling the balance between osteoblastogenesis and adipogenesis

Bone

Volumn 50, Issue 2, 2012, Pages 540-545

  Abdallah, Basem M ^a   Kassem, Moustapha ^a,b  

^a UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Adipocyte; Dlk1; Osteoblast; Pref 1; SFRP 1

Indexed keywords

ESTROGEN; FETAL ANTIGEN; FETAL ANTIGEN 1; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 7; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; SECRETED FRIZZLED RELATED PROTEIN 1; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WNT PROTEIN;

ADIPOCYTE; ADIPOGENESIS; ARTICLE; BONE DEVELOPMENT; BONE MARROW CELL; BONE MASS; CELL DIFFERENTIATION; CELL FUNCTION; CELL POPULATION; CELL STRUCTURE; CELL SURFACE; CHONDROGENESIS; DEVELOPMENTAL GENE; FETAL ANTIGEN 1 GENE; GENE EXPRESSION REGULATION; GENE FUNCTION; HORMONE ACTION; HORMONE SYNTHESIS; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STROMA CELL;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; BONE MARROW CELLS; HUMANS; OSTEOBLASTS; OSTEOGENESIS; PROTEINS;

EID: 84855892759     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.06.030     Document Type: Article

References (81)

1. Gimble J.M., Zvonic S., Floyd Z.E., Kassem M., Nuttall M.E. Playing with bone and fat. J Cell Biochem 2006, 98:251-266.
2. Takeda S., Elefteriou F., Karsenty G. Common endocrine control of body weight, reproduction, and bone mass. Annu Rev Nutr 2003, 23:403-411.
3. Chan G.K., Duque G. Age-related bone loss: old bone, new facts. Gerontology 2002, 48:62-71.
4. Tchkonia T., Giorgadze N., Pirtskhalava T., Tchoukalova Y., Karagiannides I., Forse R.A., DePonte M., Stevenson M., Guo W., Han J., Waloga G., Lash T.L., Jensen M.D., Kirkland J.L. Fat depot origin affects adipogenesis in primary cultured and cloned human preadipocytes. Am J Physiol Regul Integr Comp Physiol 2002, 282:R1286-R1296.
5. Qiu W., Andersen T.E., Bollerslev J., Mandrup S., Abdallah B.M., Kassem M. Patients with high bone mass phenotype exhibit enhanced osteoblast differentiation and inhibition of adipogenesis of human mesenchymal stem cells. J Bone Miner Res 2007, 22:1720-1731.
6. Dominici M., Le B.K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-317.
7. Abdallah B.M., Kassem M. The use of mesenchymal (skeletal) stem cells for treatment of degenerative diseases: current status and future perspectives. J Cell Physiol 2009, 218:9-12.
8. Bianco P., Robey P.G., Simmons P.J. Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008, 2:313-319.
9. Rickard D.J., Kassem M., Hefferan T.E., Sarkar G., Spelsberg T.C., Riggs B.L. Isolation and characterization of osteoblast precursor cells from human bone marrow. J Bone Miner Res 1996, 11:312-324.
10. Hong J.H., Hwang E.S., McManus M.T., Amsterdam A., Tian Y., Kalmukova R., Mueller E., Benjamin T., Spiegelman B.M., Sharp P.A., Hopkins N., Yaffe M.B. TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. Science 2005, 309:1074-1078.
11. Akune T., Ohba S., Kamekura S., Yamaguchi M., Chung U.I., Kubota N., Terauchi Y., Harada Y., Azuma Y., Nakamura K., Kadowaki T., Kawaguchi H. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004, 113:846-855.
12. Sabatakos G., Sims N.A., Chen J., Aoki K., Kelz M.B., Amling M., Bouali Y., Mukhopadhyay K., Ford K., Nestler E.J., Baron R. Overexpression of DeltaFosB transcription factor(s) increases bone formation and inhibits adipogenesis2. Nat Med 2000, 6:985-990.
13. Taipaleenmaki H., Abdallah B.M., Aldahmash A., Saamanen A.M., Kassem M. Wnt signalling mediates the cross-talk between bone marrow derived pre-adipocytic and pre-osteoblastic cell populations. Exp Cell Res 2011, 317:745-756.
14. Beresford J.N., Bennett J.H., Devlin C., Leboy P.S., Owen M.E. Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures. J Cell Sci 1992, 102(Pt 2):341-351.
15. Falconi D., Oizumi K., Aubin J.E. Leukemia inhibitory factor influences the fate choice of mesenchymal progenitor cells. Stem Cells 2007, 25:305-312.
16. Gimble J.M., Morgan C., Kelly K., Wu X., Dandapani V., Wang C.S., Rosen V. Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells. J Cell Biochem 1995, 58:393-402.
17. Kang S., Bennett C.N., Gerin I., Rapp L.A., Hankenson K.D., MacDougald O.A. Wnt signaling stimulates osteoblastogenesis of mesenchymal precursors by suppressing CCAAT/enhancer-binding protein alpha and peroxisome proliferator-activated receptor gamma. J Biol Chem 2007, 282:14515-14524.
18. Bowers R.R., Lane M.D. A role for bone morphogenetic protein-4 in adipocyte development. Cell Cycle 2007, 6:385-389.
19. Huang H., Song T.J., Li X., Hu L., He Q., Liu M., Lane M.D., Tang Q.Q. BMP signaling pathway is required for commitment of C3H10T1/2 pluripotent stem cells to the adipocyte lineage. Proc Natl Acad Sci USA 2009, 106:12670-12675.
20. Kang Q., Song W.X., Luo Q., Tang N., Luo J., Luo X., Chen J., Bi Y., He B.C., Park J.K., Jiang W., Tang Y., Huang J., Su Y., Zhu G.H., He Y., Yin H., Hu Z., Wang Y., Chen L., Zuo G.W., Pan X., Shen J., Vokes T., Reid R.R., Haydon R.C., Luu H.H., He T.C. A comprehensive analysis of the dual roles of BMPs in regulating adipogenic and osteogenic differentiation of mesenchymal progenitor cells. Stem Cells Dev 2009, 18:545-559.
21. Neumann K., Endres M., Ringe J., Flath B., Manz R., Haupl T., Sittinger M., Kaps C. BMP7 promotes adipogenic but not osteo-/chondrogenic differentiation of adult human bone marrow-derived stem cells in high-density micro-mass culture. J Cell Biochem 2007, 102:626-637.
22. Harslof T., Wamberg L., Moller L., Stodkilde-Jorgensen H., Ringgaard S., Pedersen S.B., Langdahl B.L. Rosiglitazone decreases bone mass and bone marrow fat. J Clin Endocrinol Metab 2011, 96:1541-1548.
23. Tornvig L., Mosekilde L.I., Justesen J., Falk E., Kassem M. Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int 2001, 69:46-50.
24. Rzonca S.O., Suva L.J., Gaddy D., Montague D.C., Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004, 145:401-406.
25. Kuznetsov S.A., Krebsbach P.H., Satomura K., Kerr J., Riminucci M., Benayahu D., Robey P.G. Single-colony derived strains of human marrow stromal fibroblasts form bone after transplantation in vivo. J Bone Miner Res 1997, 12:1335-1347.
26. Larsen K.H., Frederiksen C.M., Burns J.S., Abdallah B.M., Kassem M. Identifying a molecular phenotype for bone marrow stromal cells with in vivo bone forming capacity. J Bone Miner Res 2009, 25(4):796-808.
27. Beresford J.N. Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop Relat Res 1989, 270-280.
28. Bennett J.H., Joyner C.J., Triffitt J.T., Owen M.E. Adipocytic cells cultured from marrow have osteogenic potential. J Cell Sci 1991, 99(Pt 1):131-139.
29. Gronthos S., Zannettino A.C., Hay S.J., Shi S., Graves S.E., Kortesidis A., Simmons P.J. Molecular and cellular characterisation of highly purified stromal stem cells derived from human bone marrow. J Cell Sci 2003, 116:1827-1835.
30. Muraglia A., Cancedda R., Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000, 113(Pt 7):1161-1166.
31. Russell K.C., Phinney D.G., Lacey M.R., Barrilleaux B.L., Meyertholen K.E., O'Connor K.C. In vitro high-capacity assay to quantify the clonal heterogeneity in trilineage potential of mesenchymal stem cells reveals a complex hierarchy of lineage commitment. Stem Cells 2010, 28:788-798.
32. Post S., Abdallah B.M., Bentzon J.F., Kassem M. Demonstration of the presence of independent pre-osteoblastic and pre-adipocytic cell populations in bone marrow-derived mesenchymal stem cells. Bone 2008, 43:32-39.
33. Cirmanova V., Bayer M., Starka L., Zajickova K. The effect of leptin on bone: an evolving concept of action. Physiol Res 2008, 57(Suppl 1):S143-S151.
34. Moon R.T., Bowerman B., Boutros M., Perrimon N. The promise and perils of Wnt signaling through beta-catenin. Science 2002, 296:1644-1646.
35. Westendorf J.J., Kahler R.A., Schroeder T.M. Wnt signaling in osteoblasts and bone diseases. Gene 2004, 341:19-39.
36. Montcouquiol M., Crenshaw E.B., Kelley M.W. Noncanonical Wnt signaling and neural polarity. Annu Rev Neurosci 2006, 29:363-386.
37. Jones S.E., Jomary C. Secreted frizzled-related proteins: searching for relationships and patterns. Bioessays 2002, 24:811-820.
38. Gaur T., Rich L., Lengner C.J., Hussain S., Trevant B., Ayers D., Stein J.L., Bodine P.V., Komm B.S., Stein G.S., Lian J.B. Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation. J Cell Physiol 2006, 208:87-96.
39. Yao W., Cheng Z., Shahnazari M., Dai W., Johnson M.L., Lane N.E. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J Bone Miner Res 2010, 25:190-199.
40. Kumar S., Coenen M.J., Scherer P.E., Bahn R.S. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2004, 89:930-935.
41. Lagathu C., Christodoulides C., Virtue S., Cawthorn W.P., Franzin C., Kimber W.A., Nora E.D., Campbell M., Medina-Gomez G., Cheyette B.N., Vidal-Puig A.J., Sethi J.K. Dact1, a nutritionally regulated preadipocyte gene, controls adipogenesis by coordinating the Wnt/beta-catenin signaling network. Diabetes 2009, 58:609-619.
42. Lagathu C., Christodoulides C., Tan C.Y., Virtue S., Laudes M., Campbell M., Ishikawa K., Ortega F., Tinahones F.J., Fernandez-Real J.M., Oresic M., Sethi J.K., Vidal-Puig A. Secreted frizzled-related protein 1 regulates adipose tissue expansion and is dysregulated in severe obesity. Int J Obes (Lond) 2010, 34:1695-1705.
43. Smas C.M., Sul H.S. Pref-1, a protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993, 73:725-734.
44. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation3. Histol Histopathol 2000, 15:119-129.
45. Artavanis-Tsakonas S., Matsuno K., Fortini M.E. Notch signaling. Science 1995, 268:225-232.
46. Jarriault S., Brou C., Logeat F., Schroeter E.H., Kopan R., Israel A. Signalling downstream of activated mammalian Notch. Nature 1995, 377:355-358.
47. Kotzot D. Abnormal phenotypes in uniparental disomy (UPD): fundamental aspects and a critical review with bibliography of UPD other than 15. Am J Med Genet 1999, 82:265-274.
48. Berends M.J., Hordijk R., Scheffer H., Oosterwijk J.C., Halley D.J., Sorgedrager N. Two cases of maternal uniparental disomy 14 with a phenotype overlapping with the Prader-Willi phenotype. Am J Med Genet 1999, 84:76-79.
49. Wang Y., Sul H.S. Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol Cell Biol 2006, 26:5421-5435.
50. Mei B., Zhao L., Chen L., Sul H.S. Only the large soluble form of preadipocyte factor-1 (Pref-1), but not the small soluble and membrane forms, inhibits adipocyte differentiation: role of alternative splicing. Biochem J 2002, 364:137-144.
51. Sul H.S., Smas C., Mei B., Zhou L. Function of pref-1 as an inhibitor of adipocyte differentiation. Int J Obes Relat Metab Disord 2000, 24(Suppl 4):S15-S19.
52. Garces C., Ruiz-Hidalgo M.J., Bonvini E., Goldstein J., Laborda J. Adipocyte differentiation is modulated by secreted delta-like (dlk) variants and requires the expression of membrane-associated dlk. Differentiation 1999, 64:103-114.
53. Lee K., Villena J.A., Moon Y.S., Kim K.H., Lee S., Kang C., Sul H.S. Inhibition of adipogenesis and development of glucose intolerance by soluble preadipocyte factor-1 (Pref-1). J Clin Invest 2003, 111:453-461.
54. Manzoni M.F., Pramparo T., Stroppolo A., Chiaino F., Bosi E., Zuffardi O., Carrozzo R. A patient with maternal chromosome 14 UPD presenting with a mild phenotype and MODY. Clin Genet 2000, 57:406-408.
55. Hordijk R., Wierenga H., Scheffer H., Leegte B., Hofstra R.M., Stolte-Dijkstra I. Maternal uniparental disomy for chromosome 14 in a boy with a normal karyotype. J Med Genet 1999, 36:782-785.
56. Abdallah B.M., Jensen C.H., Gutierrez G., Leslie R.G., Jensen T.G., Kassem M. Regulation of human skeletal stem cells differentiation by Dlk1/Pref-1. J Bone Miner Res 2004, 19:841-852.
57. Abdallah B.M., Ditzel N., Mahmood A., Isa A., Traustadottir G.A., Schilling A.F., Ruiz-Hidalgo M., Laborda J., Amling M., Kassem M. DLK1 is a novel regulator of bone mass that mediates estrogen-deficiency induced bone loss in mice. J Bone Miner Res 2011, 26(7):1457-1471.
58. Bauer S.R., Ruiz-Hidalgo M.J., Rudikoff E.K., Goldstein J., Laborda J. Modulated expression of the epidermal growth factor-like homeotic protein dlk influences stromal-cell-pre-B-cell interactions, stromal cell adipogenesis, and pre-B-cell interleukin-7 requirements. Mol Cell Biol 1998, 18:5247-5255.
59. Hackney J.A., Charbord P., Brunk B.P., Stoeckert C.J., Lemischka I.R., Moore K.A. A molecular profile of a hematopoietic stem cell niche. Proc Natl Acad Sci USA 2002, 99:13061-13066.
60. Raghunandan R., Ruiz-Hidalgo M., Jia Y., Ettinger R., Rudikoff E., Riggins P., Farnsworth R., Tesfaye A., Laborda J., Bauer S.R. Dlk1 influences differentiation and function of B lymphocytes. Stem Cells Dev 2008, 17:495-507.
61. Kalajzic I., Kalajzic Z., Kaliterna M., Gronowicz G., Clark S.H., Lichtler A.C., Rowe D. Use of type I collagen green fluorescent protein transgenes to identify subpopulations of cells at different stages of the osteoblast lineage. J Bone Miner Res 2002, 17:15-25.
62. Pacifici R. T cells and post menopausal osteoporosis in murine models. Arthritis Res Ther 2007, 9:102.
63. van Roon J.A., Glaudemans K.A., Bijlsma J.W., Lafeber F.P. Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:113-119.
64. Weitzmann M.N., Pacifici R. Estrogen regulation of immune cell bone interactions. Ann N Y Acad Sci 2006, 1068:256-274.
65. Tsubaki M., Kato C., Manno M., Ogaki M., Satou T., Itoh T., Kusunoki T., Tanimori Y., Fujiwara K., Matsuoka H., Nishida S. Macrophage inflammatory protein-1alpha (MIP-1alpha) enhances a receptor activator of nuclear factor kappaB ligand (RANKL) expression in mouse bone marrow stromal cells and osteoblasts through MAPK and PI3K/Akt pathways. Mol Cell Biochem 2007, 304:53-60.
66. Fazeli P.K., Bredella M.A., Misra M., Meenaghan E., Rosen C.J., Clemmons D.R., Breggia A., Miller K.K., Klibanski A. Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. J Clin Endocrinol Metab 2010, 95:407-413.
67. Harkness L., Taipaleenmaki H., Mahmood A., Frandsen U., Saamanen A.M., Kassem M., Abdallah B.M. Isolation and differentiation of chondrocytic cells derived from human embryonic stem cells using dlk1/FA1 as a novel surface marker. Stem Cell Rev Rep 2009, 5(4):353-368.
68. Wang Y., Sul H.S. Pref-1 regulates mesenchymal cell commitment and differentiation through Sox9. Cell Metab 2009, 9:287-302.
69. Takayanagi H. Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 2009, 5:667-676.
70. Carrel A.L., Allen D.B. Effects of growth hormone on body composition and bone metabolism. Endocrine 2000, 12:163-172.
71. Abdallah B.M., Ding M., Jensen C.H., Ditzel N., Flyvbjerg A., Jensen T.G., Dagnaes-Hansen F., Gasser J.A., Kassem M. Dlk1/FA1 is a novel endocrine regulator of bone and fat mass and its serum level is modulated by growth hormone. Endocrinology 2007, 148:3111-3121.
72. Modder U.I., Roforth M.M., Hoey K., McCready L.K., Peterson J.M., Monroe D.G., Oursler M.J., Khosla S. Effects of estrogen on osteoprogenitor cells and cytokines/bone-regulatory factors in postmenopausal women. Bone 2011.
73. Abdallah B.M., Bay-Jensen A., Srinivasan B., Tabassi N.C., Garnero P., Delaisse J., Khosla S., Kassem M. Estrogen inhibits Dlk1/FA1 production: a potential mechanism for estrogen effects on bone turnover. J Bone Miner Res 2011, 10.1002/jbmr.444.
74. Abdallah B.M., Boissy P., Tan Q., Dahlgaard J., Traustadottir G.A., Kupisiewicz K., Laborda J., Delaisse J.M., Kassem M. dlk1/FA1 regulates the function of human bone marrow mesenchymal stem cells by modulating gene expression of pro-inflammatory cytokines and immune response-related factors. J Biol Chem 2007, 282:7339-7351.
75. Ishibashi M., Moriyoshi K., Sasai Y., Shiota K., Nakanishi S., Kageyama R. Persistent expression of helix-loop-helix factor HES-1 prevents mammalian neural differentiation in the central nervous system. EMBO J 1994, 13:1799-1805.
76. Simpson P. Developmental genetics. The Notch connection. Nature 1995, 375:736-737.
77. Nueda M.L., Baladron V., Sanchez-Solana B., Ballesteros M.A., Laborda J. The EGF-like protein dlk1 inhibits notch signaling and potentiates adipogenesis of mesenchymal cells. J Mol Biol 2007, 367:1281-1293.
78. Nueda M.L., Garcia-Ramirez J.J., Laborda J., Baladron V. dlk1 specifically interacts with insulin-like growth factor binding protein 1 to modulate adipogenesis of 3T3-L1 cells. J Mol Biol 2008, 379:428-442.
79. Zhang H., Noohr J., Jensen C.H., Petersen R.K., Bachmann E., Teisner B., Larsen L.K., Mandrup S., Kristiansen K. Insulin-like growth factor-1/insulin bypasses Pref-1/FA1-mediated inhibition of adipocyte differentiation. J Biol Chem 2003, 278:20906-20914.
80. Ruiz-Hidalgo M.J., Gubina E., Tull L., Baladron V., Laborda J. dlk modulates mitogen-activated protein kinase signaling to allow or prevent differentiation. Exp Cell Res 2002, 274:178-188.
81. Wang Y., Zhao L., Smas C., Sul H.S. Pref-1 interacts with fibronectin to inhibit adipocyte differentiation. Mol Cell Biol 2010, 30:3480-3492.